Copy Link Print Information

Lorlatinib

(Synonyms: PF-06463922)
38 Cited Publications
Avis client

Based on 38 publication(s) in Google Scholar

Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor with anticancer activity. Lorlatinib has Kis of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALKL1196M, respectively. Lorlatinib targets to EML4-ALK, and inhibits ALK phosphorylation with IC50s of 15-43 nM (ALKL1196), 14-80 nM (ALKG1269A), 38-50 nM (ALK1151Tins), 77-113 nM (ALKG1202R), respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.99%
  • CAS No.: 1454846-35-5
  • Formule: C21H19FN6O2
  • Masse moléculaire:406.41
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Lorlatinib Chemical Structure
    Lorlatinib Chemical Structure
  • Experimental Validation Results for Lorlatinib
  • Experimental Validation Results for Lorlatinib
  • Experimental Validation Results for Lorlatinib
  • Experimental Validation Results for Lorlatinib
  • Experimental Validation Results for Lorlatinib
CAS No.: 1454846-35-5
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Lorlatinib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Protocole
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Lorlatinib

More
Customer Validation & Images
In Vivo Efficacy StudyCell Proliferation/Viability AssayCell Imaging/StainingWB
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Imaging/Staining
  • WB
  • Cell Proliferation/Viability Assay
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Lorlatinib Chemical Structure
    Lorlatinib Chemical Structure
    1/16
  • 1/16

    Lorlatinib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2024 Dec 2;14(12):2367-2386. [Abstract]

    Customer Validation
     Lorlatinib (10 mg/kg; oral; daily). Change in tumor volume over time plotted as mean ± SEM for models harboring ALK fusion with a WT kinase domain.

  • 1/16

    Lorlatinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227. [Abstract]

    Customer Validation
     Representative images of clonogenic assay results in PARP inhibitor (PARPi)-resistant OVCA433 cell in the presence of the indicated inhibitor for 12 d. ALKi, ALK inhibitor; LOR, Lorlatinib (250-500 nM); TALA, Talazoparib (100-200 nM); Comb, combination of Lorlatinib and Talazoparib.

  • 1/16

    Lorlatinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227. [Abstract]

    Customer Validation
     Representative images of RAD51 with EdU/DAPI staining in OVCA433 cell treated with 0.25 μM PARP inhibitor (PARPi; Talazoparib) or 0.5 μM ALK inhibitor (ALKi; Lorlatinib), either alone or in combination, for 48 h.

  • 1/16

    Lorlatinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227. [Abstract]

    Customer Validation
     WB of indicated proteins in cells treated with or without 0.5 μM ALK inhibitor (Lorlatinib) for 24 h.

  • 1/16

    Lorlatinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 Oct 30;8(1):1197. [Abstract]

    Customer Validation
     Lorlatinib (100 nM; 72 h). Representative photographs of soft agar colony formation assay.

  • Lorlatinib